Schering announces start of three Phase II clinical trials with anti-cancer compound ZK-EPO
European trials will assess ZK-EPO in non-small cell lung, ovarian and breast cancers
In non-small cell lung cancer, a multi-center study is currently enrolling patients in Germany. The trial is designed to examine the efficacy and safety of ZK-EPO as second-line therapy in patients with advanced disease.
The ovarian cancer trial is a multi-center Phase II study that is being conducted in the United Kingdom. The study is currently enrolling patients with recurrent ovarian cancer.
The breast cancer trial will enroll patients in 24 medical centers in a number of European countries. The first study centers have been initiated in France and Austria. The trial will investigate the efficacy of ZK-EPO in patients with metastatic breast cancer.
Additional studies with ZK-EPO are being planned in the United States and the EU.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.